Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
The current form, Egrifta WR, was approved in March 2025
WHAT DO I NEED TO KNOW ABOUT TRT
TRIUMPH-1 (NCT05929066, n=2,339, 80 weeks, general obesity): 28.3% average weight loss on the 12mg dose
Nonetheless, such stigmas about perceived superficial motivations for GLP-1 use may prevent patients from accessing medical treatment that could significantly improve their health and quality of life
US$ 21.50
US$ 25.48
US$ 25.79
US$ 28.24
